EHA Plenary Abstracts Zoom in From Investigational Drugs to Molecular Signatures
June 14th 2025Abstracts presented during the plenary session of the 2025 European Hematology Association (EHA) Congress spanned from novel drug regimens for myeloma and lymphoma to investigation of leukemias on the molecular and genetic levels.
Read More
Impact of COVID-19 on Specialty Televisits in a Large Integrated Health Care System
Specialty televisits remain common in the Veterans Health Administration following the COVID-19 pandemic, suggesting they will remain an important ongoing care modality for many patients.
Read More
Managed Care Reflections: A Q&A With Melinda B. Buntin, PhD
June 2nd 2025To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The June issue features a conversation with Melinda B. Buntin, PhD, a health economist and a Bloomberg Distinguished Professor at the Johns Hopkins Bloomberg School of Public Health and Carey Business School.
Read More
MRD Status Guides Consolidation With Cema-Cel in ALPHA3 Trial: Fred Locke, MD
May 20th 2025The ALPHA3 trial is exploring cemacabtagene ansegedleucel's (cema-cel) potential to enhance outcomes in patients who have relapsed/refractory large B-cell lymphoma, particularly those positive for minimal residual disease.
Watch
Digital Health Implementation Among Older Adults: Health Technology Navigators’ Perspectives
Health technology navigators share perspectives on barriers to and facilitators of digital health access for older, linguistically diverse patients in a Los Angeles safety-net system.
Read More
For Patients Who Cannot Wait, This Off-the-Shelf CAR NK Treatment for AML Leaves Healthy Cells Alone
May 12th 2025First part of a 2-part interview with Stephen Strickland, MD, MSCI, director of leukemia research for Sarah Cannon Research Institute. Strickland recently presented data from a phase 1 trial of SENTI-202, an investigational chimeric antigen receptor (CAR) natural killer (NK) cell therapy.
Read More
Black Youths Overlabeled High Risk in Mental Health Emergencies
May 9th 2025Despite similar scores on an aggression risk evaluation tool in a pediatric emergency department, Black youths were significantly more likely to be labeled with a high aggression risk behavioral health flag in their electronic health records compared with White youths.
Read More
This study compared 6 algorithmic fairness–improving approaches for low-birth-weight predictive models and found that they improved accuracy but decreased sensitivity for Black populations.
Read More
The Need to Validate AI Tools in the Pharmacy: Harry Travis
May 6th 2025To safely and successfully use artificial intelligence (AI) tools in the pharmacy, credentialing bodies and professional associations will need to validate these tools for the individual pharmacist, said Harry Travis of The Travis Group.
Watch
Effect of Remote Patient Monitoring on Stage 2 Hypertension
May 6th 2025A community-based remote patient monitoring (RPM) program was associated with significant reduction in blood pressure in Medicare patients with stage 2 hypertension, highlighting the potential benefits of RPM with care coaching.
Read More
AXS25: Health Policy, Drug Costs, and AI Highlights From the Conference
May 6th 2025Asembia’s AXS25 Summit covered a variety of relevant topics in the pharmaceutical industry, from the effects of the new administration to how artificial intelligence (AI) is reshaping the patience experience.
Read More